Discovery of brain-penetrant, irreversible kynurenine aminotransferase ii inhibitors for schizophrenia

ACS Medicinal Chemistry Letters

Volumn 3, Issue 3, 2012, Pages 187-192

  Dounay, Amy B ^a   Anderson, Marie ^a   Bechle, Bruce M ^a   Campbell, Brian M ^a   Claffey, Michelle M ^a   Evdokimov, Artem ^a   Evrard, Edelweiss ^a   Fonseca, Kari R ^a   Gan, Xinmin ^a   Ghosh, Somraj ^a   Hayward, Matthew M ^a   Horner, Weldon ^a   Kim, Ji Young ^a   McAllister, Laura A ^a   Pandit, Jayvardhan ^a   Paradis, Vanessa ^a   Parikh, Vinod D ^a   Reese, Matthew R ^a   Rong, Suobao ^a   Salafia, Michelle A ^a   Schuyten, Katherine ^a   Strick, Christine A ^a   Tuttle, Jamison B ^a   Valentine, James ^a   Wang, Hong ^a   Zawadzke, Laura E ^a   Verhoest, Patrick R ^a   more..

^a PFIZER INC   (United States)

Author keywords

hydroxamic acid; KAT II; kynurenic acid; kynurenine aminotransferase

Indexed keywords

3 AMINO 1 HYDROXY 3,4 DIHYDROQUINOLIN 2(1H) ONE; KYNURENIC ACID; KYNURENINE AMINOTRANSFERASE; KYNURENINE AMINOTRANSFERASE 2; NEUROLEPTIC AGENT; PF 04859989; PYRIDOXAL 5 PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL MODIFICATION; CONTROLLED STUDY; COVALENT BOND; DRUG EFFICACY; DRUG PENETRATION; DRUG STABILITY; ENZYME ACTIVE SITE; HIGH THROUGHPUT SCREENING; HUMAN; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

RATTUS;

EID: 84863267354     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml200204m     Document Type: Article

References (35)

1. Hilmas, C.; Pereira, E. F.; Alkondon, M.; Rassoulpour, A.; Schwarcz, R.; Albuquerque, E. X. The Brain Metabolite Kynurenic Acid Inhibits α7 Nicotinic Receptor Activity and Increases Non-α7 Nicotinic Receptor Expression: Physiopathological Implications J. Neurosci. 2001, 21, 7463-7473 (Pubitemid 32904945)
2. Kessler, M.; Terramani, T.; Lynch, G.; Baudry, M. A Glycine Site Associated with N-Methyl-D-Aspartic Acid Receptors: Characterization and Identification of a New Class of Antagonists J. Neurochem. 1989, 52, 1319-1328 (Pubitemid 19085960)
3. Natale, B. C.; Murray, I. A.; Schroeder, J. C.; Flaveny, C. A.; Lahoti, T. S.; Laurenzana, E. M.; Omiecinski, C. J.; Perdew, G. H. Kynurenic Acid Is a Potent Endogenous Aryl Hydrocarbon Receptor Ligand that Synergistically Induces Interleukin-6 in the Presence of Inflammatory Signaling Toxicol. Sci. 2010, 115, 89-97
4. Erhardt, S.; Schwieler, L.; Nilsson, L.; Linderholm, K.; Engberg, G. The Kynurenic Acid Hypothesis of Schizophrenia Physiol. Behav. 2007, 92, 203-209 (Pubitemid 47374246)
5. Erhardt, S.; Olsson, S. K.; Engberg, G. Pharmacological Manipulation of Kynurenic Acid: Potential in the Treatment of Psychiatric Disorders CNS Drugs 2009, 23, 91-101
6. Potter, M. C.; Elmer, G. I.; Bergeron, R.; Albuquerque, E.; Guidetti, P.; Wu, H.-Q.; Schwarcz, R. Reduction of Endogenous Kynurenic Acid Formation Enhances Extracellular Glutamate, Hippocampal Plasticity, and Cognitive Behavior Neuropsychopharmacology 2010, 35, 1734-1742
7. Erhardt, S.; Blennow, K.; Nordin, C.; Skogh, E.; Lindstrom, L. H.; Engberg, G. Kynurenic Acid Levels Are Elevated in the Cerebrospinal Fluid of Patients with Schizophrenia Neurosci. Lett. 2001, 313, 96-98 (Pubitemid 32973903)
8. Nilsson, L. K.; Linderholm, K. R.; Engberg, G.; Paulson, L.; Blennow, K.; Lindstrom, L. H.; Nordin, C.; Karanti, A.; Persson, P.; Erhardt, S. Elevated Levels of Kynurenic Acid in the Cerebrospinal Fluid of Male Patients with Schizophrenia Schizophr. Res. 2005, 80, 315-322 (Pubitemid 41713657)
9. Schwarcz, R.; Rassoulpour, A.; Wu, H.-Q.; Medoff, D.; Tamminga, C. A.; Roberts, R. C. Increased Cortical Kynurenate Content in Schizophrenia Biol. Psychiatry 2001, 50, 521-530 (Pubitemid 32971883)
10. Olsson, S. K.; Samuelsson, M.; Saetre, P.; Lindstrom, L.; Jonsson, E. G.; Nordin, C.; Engberg, G.; Erhardt, S.; Landen, M. Elevated Levels of Kynurenic Acid in the Cerebrospinal Fluid of Patients with Bipolar Disorder J. Psychiatry Neurosci. 2010, 35, 195-199
11. For a recent review, see Han, Q.; Cai, T.; Tagle, D. A.; Li, J. Structure, Expression, and Function of Kynurenine Aminotransferases in Human and Rodent Brains Cell. Mol. Life Sci. 2010, 67, 353-368
12. Rossi, F.; Garavaglia, S.; Montalbano, V.; Walsh, M. A.; Rizzi, M. Crystal Structure of Human Kynurenine Aminotransferase II, a Drug Target for the Treatment of Schizophrenia J. Biol. Chem. 2008, 283, 3559-3566
13. Rossi, F.; Valentina, C.; Garavaglia, S.; Sathyasaikumar, K. V.; Schwarz, R.; Kojima, S.; Okuwaki, K.; Ono, S.; Kajii, Y.; Rizzi, M. Crystal Structure-Based Selective Targeting of the Pyridoxal 5â€-Phosphate Dependent Enzyme Kynurenine Aminotransferase II for Cognitive Enhancement J. Med. Chem. 2010, 53, 5684-5689
14. Pellicciari, R.; Rizzo, R. C.; Costantino, G.; Marinozzi, M.; Amori, L.; Guidetti, P.; Wu, H.-Q.; Schwarcz, R. Modulators of the Kynurenine Pathway of Tryptophan Metabolism: Synthesis and Preliminary Biological Evaluation of (S)-4-(Ethylsulfonyl)-benzoylalanine, a Potent and Selective Kynurenine Aminotransferase II (KAT II) Inhibitor ChemMedChem 2006, 1, 528-531 (Pubitemid 43759763)
15. Amori, L.; Wu, H.-Q.; Marinozzi, M.; Pellicciari, R.; Guidetti, P.; Schwarcz, R. Specific Inhibition of Kynurenate Synthesis Enhances Extracellular Dopamine Levels in the Rodent Striatum Neuroscience 2009, 156, 196-203
16. Amori, L.; Guidetti, P.; Pellicciari, R.; Kajii, Y.; Schwarcz, R. On the Relationship Between the Two Branches of the Kynurenine Pathway in the Rat Brain In Vivo J. Neurochem. 2009, 109, 316-325
17. Wu, H.-Q.; Pereira, E. F. R.; Bruno, J. P.; Pellicciari, R.; Albuquerque, E. X.; Schwarcz, R. The Astrocyte-Derived α7 Nicotinic Receptor Antagonist Kynurenic Acid Controls Extracellular Glutamate Levels in the Prefrontal Cortex J. Mol. Neurosci. 2010, 40, 204-210
18. Schwarcz, R.; Kajii, Y.; Ono, S. Preparation of aminopiperazinylquinolonecarboxylates as kynurenine-amino-transferase inhibitors. WO 2009064836.
19. Pellicciari, R.; Venturoni, F.; Bellocchi, D.; Carotti, A.; Marinozzi, M.; Macchiarulo, A.; Amori, L.; Schwarcz, R. Sequence Variants in Kynurenine Aminotransferase II (KAT II) Orthologs Determine Different Potencies of the Inhibitor (S)-ESBA ChemMedChem 2008, 3, 1199-1202
20. Casazza, V.; Rossi, F.; Rizzi, M. Biochemical and structural investigations on kynurenine aminotransferase II: an example of conformation-driven species-specific inhibition? Curr. Top. Med. Chem. 2011, 11, 148-157
21. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand Efficiency: A Useful Metric for Lead Selection Drug Discovery Today 2004, 9, 430-431 (Pubitemid 38510559)
22. KeseruÌ̂, G. M.; Makara, G. M. The Influence of Lead Discovery Strategies on the Properties of Drug Candidates Nat. Rev. Drug Discovery 2009, 8, 203-212
23. Price, D. A.; Blagg, J.; Jones, L.; Greene, N.; Wager, T. Physicochemical Drug Properties Associated with In Vivo Toxicological Outcomes: A Review Expert Opin. Drug Metab. Toxicol. 2009, 5, 921-931
24. Edwards, M. P.; Price, D. A. Role of physicochemical properties and ligand lipophilicity efficiency in addressing drug safety risks Annu. Rep. Med. Chem. 2010, 45, 381-391
25. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its applications to the prediction of drug transport properties J. Med. Chem. 2000, 43, 3714-3717
26. Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties ACS Chem. Neurosci. 2010, 1, 435-449
27. Wager, T. T.; Chandrasekaran, R. Y.; Hou, X.; Troutman, M. D.; Verhoest, P. R.; Villalobos, A.; Will, Y. Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes ACS Chem. Neurosci. 2010, 1, 420-434
28. Anderson, M. Personal communication, Pfizer.
29. Olson, G. T.; Fu, M.; Lau, S.; Rinehart, K. L.; Silverman, R. B. An Aromatization Mechanism of Inactivation of Gamma-Aminobutyric Acid Aminotransferase for the Antibiotic l -Cycloserine J. Am. Chem. Soc. 1998, 120, 2256-2267 (Pubitemid 28149772)
30. ACD Labs 9.0.
31. Johnson, D. S.; Weerapana, E.; Cravatt, B. F. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors Future Med. Chem. 2010, 2, 949-964
32. Singh, J.; Petter, R. C.; Baillie, T. A.; Whitty, A. The Resurgence of Covalent Drugs Nat. Rev. Drug Discovery 2011, 10, 307-317
33. Claffey, M. M.; Dounay, A. B.; Gan, X.; Hayward, M. M.; Rong, S.; Tuttle, J. B.; Verhoest, P. R. Bicyclic and Tricyclic Compounds as KAT II Inhibitors. WO2010146488.
34. McAllister, L. A.; Bechle, B. M.; Dounay, A. B.; Evrard, E.; Gan, X.; Ghosh, S.; Kim, J.-Y.; Parikh, V. D.; Tuttle, J. B.; Verhoest, P. R. A General Strategy for the Synthesis of Cyclic N -Aryl Hydroxamic Acids via Partial Nitro Group Reduction J. Org. Chem. 2011, 76, 3484-3497
35. Copeland, R. A. Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists; Wiley: Hoboken, NJ, 2005; pp 1-265.